Senate Bill 989
Senate Author: Huffman et al.
Effective: 9-1-23
House Sponsor: Bonnen et al.
Senate Bill 989 amends the Insurance Code to require a health benefit plan to provide coverage for biomarker testing for the purpose of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition to guide treatment when the test is supported by certain kinds of medical and scientific evidence. A health benefit plan must provide such coverage in a manner that limits disruptions in care and a health benefit plan issuer must provide the coverage only when use of biomarker testing provides clinical utility because use of the test for the condition is evidence‑based and scientifically valid, informs a patient's outcome and a provider's clinical decision, and predominately addresses the issue for which the test is being ordered, though a test may include some information that cannot be immediately used in clinical decision‑making.